With the annual ADA confab only, a few weeks away an early betting line is emerging as to what the BIG story will be. Should form follow function the biggest story coming out of the show will be a story that happens at the show that no one saw coming. Throwing away these unanticipated/surprise events we do see some stories dominating the news cycle while we’re in steamy Orlando.
Yesterday Novo Nordisk (NYSE: NVO) took a major step to be a headliner when they released data from PIONEER 2, the second phase 3a trial with oral semaglutide. In . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.